Xanthus Pharmaceuticals

The company's revenue generation model was centered on the successful clinical development and subsequent commercialization or out-licensing of its therapeutic assets. Xanthus actively pursued in-licensing opportunities to expand its pipeline, as demonstrated by its agreement with Schering AG in 2006 to gain exclusive U.S. rights for the development and commercialization of oral fludarabine. This product, already marketed outside the U.S., represented a near-term commercial opportunity for treating chronic lymphocytic leukemia (CLL). The company's portfolio was diverse, targeting significant unmet medical needs. A key asset was Xanafide, a DNA-intercalating agent in a pivotal Phase III trial for secondary acute myeloid leukemia (sAML), an indication with no specifically approved drugs at the time. Other candidates included Symadex for metastatic breast cancer, and compounds targeting non-small cell lung cancer and solid tumors.

Throughout its operation, Xanthus secured significant financial backing, raising approximately $88 million in venture capital from a syndicate of investors including HealthCare Ventures, Gimv, and CDIB BioScience Venture Management. This funding enabled the company to advance its drug candidates, including operating facilities in both Cambridge and Montreal. In May 2008, a definitive agreement was reached for Xanthus to be acquired by Antisoma plc, a UK-based cancer-focused biotechnology company. The all-share transaction was valued at approximately $52.2 million. The acquisition was positioned as a transforming deal, creating a combined entity with a more mature and diverse pipeline, including two Phase III drugs and one product in registration, thereby increasing the potential to bring drugs to market. The acquisition was successfully completed in June 2008.